查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2096859

伴侶動物疫苗市場－2026-2032年全球市場預測

Companion Animal Vaccine Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，伴侶動物疫苗市場將成長至 95.4 億美元，複合年成長率為 8.48%。

主要市場統計數據
基準年 2025 53.9億美元
預計年份：2026年 58.5億美元
預測年份 2032 95.4億美元
複合年成長率 (%) 8.48%

伴侶動物疫苗市場概覽

伴侶動物疫苗的市場趨勢受到寵物數量成長、預防性獸醫保健意識增強、寵物保險覆蓋範圍擴大以及對預防通用感染疾病日益關注等因素的影響。犬、貓和其他伴侶動物的疫苗在日常健康管理方案中繼續發揮核心作用，有助於預防狂犬病、犬瘟熱、犬細小病毒、犬腺病毒、鉤端螺旋體病、貓泛白血球減少症、貓杯狀病毒、貓皰疹病毒和其他感染疾病。監管指南和獸醫協會的建議繼續區分「核心疫苗」和「非核心疫苗」。 「核心疫苗」根據疾病的嚴重程度和公共衛生重要性進行廣泛推薦，而「非核心疫苗」則根據生活方式、地理因素、感染風險和動物個體的健康狀況進行選擇。此外，都市化加快、人類與動物關係日益密切、獸醫醫院網路不斷擴展以及低溫運輸和配送能力的提升，都進一步推動了疫苗需求的成長。另一方面，該領域面臨許多挑戰，包括部分寵物飼主對疫苗接種猶豫不決、獸醫服務取得管道不均、加強免疫接種計畫執行不力，以及需要對不利事件進行透明監測。因此，該行業正轉向以循證醫學為基礎的疫苗接種策略，將臨床療效、安全監測、主人教育以及獸醫根據個體情況制定的判斷相結合。

伴侶動物疫苗領域的變革性變化

隨著獸醫學從被動治療轉向主動預防，伴侶動物疫苗領域正在經歷結構性變化。獸醫診所擴大將疫苗接種與健康檢查、寄生蟲控制、牙科護理、營養指導和電子健康記錄相結合，從而形成更規範的預防保健方法。另一項重大變革是基於風險評估的疫苗接種方案的改進。獸醫現在會評估伴侶動物的生活方式、旅行模式、在寵物旅館的接觸風險、當地疾病流行情況、年齡、繁殖狀態、免疫功能和既往疫苗接種史，而不再僅依賴標準化的接種程序。疫苗技術的進步，例如重組平台、基於載體的疫苗、改良的佐劑系統以及旨在減少操作壓力和提高依從性的聯合疫苗，也在改變整個行業的格局。公共衛生優先事項仍然是主要的驅動力，尤其是在狂犬病疫苗接種方面，在「同一健康」策略下，伴侶動物疫苗接種被認為是預防人類狂犬病的關鍵要素。疫苗接種的分發模式也在不斷發展，獸醫診所、行動診所、動物收容所、動物福利計畫和數位化預約系統等都為提高疫苗接種的便利性做出了貢獻。這些變化正在創造一個以數據驅動、本地化和以寵物飼主為中心的疫苗接種環境。

人工智慧對伴侶動物疫苗的累積影響

人工智慧 (AI) 正透過臨床決策支援、流行病學監測、藥物安全監測、客戶參與和營運效率提升等方式，開始影響伴侶動物疫苗接種。 AI 驅動的獸醫系統可以提供提醒，鼓勵寵物接種加強疫苗，識別可能錯過疫苗接種的寵物，並幫助獸醫診所根據年齡、品種、生活方式和當地疾病暴露對動物進行分類。在疾病監測方面，機器學習可用於分析診斷記錄、地理空間數據、收容所安置模式、實驗室檢測請求和公共衛生數據，以識別可能需要進行有針對性的疫苗宣傳活動的新興感染叢集。 AI 還可以透過檢測大規模資料集中的模式來增強不利事件報告系統並提高訊號識別的準確性，同時為監管機構和臨床審查提供支援。在產品開發方面，計算生物學和預測建模可以加速抗原選擇、免疫反應分析和製劑篩檢，但獸醫檢驗和向監管機構提交證據仍然至關重要。對於製造商、經銷商和獸醫服務提供者而言，AI 可以改善低溫運輸監控、庫存計劃、需求調整和預約安排。只要資料隱私、互通性、臨床監督和透明的模式管治得到維護，這些努力就能共同推動從常規疫苗接種交易轉向持續預防性醫療保健的轉變。

關於伴侶動物疫苗引進的關鍵區域性見解

亞太地區涵蓋中國、印度、日本、韓國、澳洲和東南亞，其特點是伴侶動物飼養量快速成長、都市區中產階級寵物相關支出不斷增加，以及對現代獸醫服務的需求日益成長。雖然狂犬病預防在某些國家仍然是重要的公共衛生優先事項，但高所得市場更重視優質的獸醫護理、基於生活方式的疫苗接種以及先進的診所基礎設施。北美地區的特點是獸醫網路成熟、對基本疫苗接種方案的認知度高、診斷和預防性護理服務廣泛普及，以及用於支持接種依從性的數位化提醒系統已被廣泛應用。美國和加拿大維持著完善的狂犬病控制框架，從而加強了伴侶動物疫苗接種在公共衛生中的作用。在拉丁美洲，人們高度重視狂犬病疫苗接種、犬類感染疾病預防，並透過公共宣傳活動、私人診所和動物福利計劃來擴大服務涵蓋範圍，其中巴西和墨西哥是重要的獸醫中心。歐洲的特點是獸醫標準規範、寵物人性化趨勢顯著、跨境寵物流動要求嚴格，並專注於藥物安全監測，伴侶動物疫苗接種與動物福利和疾病預防政策緊密相關。在中東，寵物數量不斷成長，高階獸醫院蓬勃發展，都市區的預防性獸醫服務也日益受到重視。尤其是在海灣國家，隨著進口寵物和外籍人士通用寵物數量的增加，寵物登記和定期疫苗接種的重要性日益凸顯。在非洲，雖然主要城市的寵物護理服務正在擴展，但人們仍然依賴狂犬病疫苗接種宣傳活動和「同一健康」計畫來降低感染疾病的風險，尤其是在那些常規獸醫服務普及程度仍然不均衡的地區。

影響伴侶動物疫苗需求的關鍵群體特定見解

在東協地區，都市區寵物擁有率的上升、獸醫服務可及性的改善以及部分成員國對狂犬病預防的持續高度重視，都影響著伴侶動物疫苗的接種率。因此，提高公眾意識、降低疫苗價格以及建立低溫運輸對於提高疫苗接種率至關重要。在海灣合作理事會（GCC）國家，伴侶動物照護呈現出優質化趨勢，這得益於外籍人士寵物數量的增加、現代化動物醫院的普及以及對預防性護理套餐需求的成長。然而，對氣候敏感的物流和依賴進口的供應鏈仍然是需要重點考慮的因素。歐盟擁有高度結構化的監管和動物健康環境，其寵物流動規則、獸藥安全監測、福利政策以及統一的標準，都為疫苗品質和合規性的保障提供了支持。金磚國家（BRICS）的需求環境多元且具影響力。中國和印度的獸醫基礎設施和寵物健康意識正在不斷提高。巴西在狂犬病和犬類疾病預防方面發揮著至關重要的作用。俄羅斯幅員遼闊，對伴侶動物照護的需求龐大。南非既支持私人獸醫服務，也重視公共衛生相關的疫苗接種工作。七國集團（G7）國家普遍擁有成熟的獸醫體系、較高的飼主意識、強大的數據基礎設施和完善的法律規範機制，這些都促進了疫苗品質、安全監測和合規工具的創新。北約成員國與北美和歐洲的先進獸醫市場高度重合，這些地區生物安全意識強、跨境流動頻繁，並擁有完善的醫療保健基礎設施，這些都為包括伴侶動物疫苗接種在內的動物健康預防措施提供了支持。

各國在引進伴侶動物疫苗的關鍵見解

美國仍然是伴侶動物疫苗接種最先進的國家之一，這得益於其完善的獸醫服務、民眾對基礎疫苗接種的高度重視、各州制定的狂犬病疫苗接種要求，以及健康計劃和數字提醒的廣泛應用。加拿大也十分重視預防性獸醫護理，狂犬病預防要求因州和地區而異，取決於風險程度。在墨西哥，私人寵物醫療保健的發展與狂犬病預防的公共衛生重要性並存。巴西擁有龐大的寵物數量和悠久的公共疫苗接種計劃歷史，尤其是在狂犬病疫苗方面，同時私人獸醫診所也在擴大對犬貓的疫苗接種範圍。在英國，重點在於循證疫苗接種方案、遵守寵物旅行法規以及寵物飼主積極參與預防性護理。德國、法國、義大利和西班牙擁有完善的獸醫基礎設施、較高的寵物擁有率以及符合歐洲動物健康標準的管理體制，這些框架都支持基礎疫苗和基於風險的疫苗的持續使用。在俄羅斯，主要大都市地區存在與伴侶動物照護相關的機遇，但地理範圍可能會影響其分佈的均勻性。在中國，人們對寵物保健的意識迅速提高，都市區的獸醫院數量不斷增加，對高品質預防服務的需求也激增。在印度，寵物數量快速成長的同時，狂犬病預防的需求也十分迫切，因此大眾教育和獸醫服務的普及至關重要。在日本，伴侶動物醫療文化根深蒂固，寵物人口老化嚴重，且普遍重視預防醫學。澳洲的優勢在於其高標準的獸醫服務、生物安全意識以及飼主對寵物健康的高投入意願。在韓國，寵物「人性化」進程迅速推進，都市區的獸醫院數量不斷增加，人們對系統性健康管理和疫苗接種計劃的興趣也持續成長。

為伴侶動物疫苗產業的領導者提供實用建議。

行業領導者應優先考慮為寵物飼主提供基於循證醫學的疫苗接種教育，強調必要疫苗和非必要疫苗的區別、按時接種加強針的重要性以及疫苗在預防通用感染疾病中的作用。獸醫相關人員應採用基於風險的方案，考慮地區、生活方式、年齡、免疫狀況、旅遊史、寄養經驗和當地疾病監測等因素，同時確保符合認可的獸醫指南和當地法規。加強低溫運輸可靠性、庫存可視性和最後一公里配送至關重要，尤其是在新興市場和對溫度敏感的物流環境地區。應透過自動提醒、電子免疫記錄、飼主教育入口網站以及與健康計劃的整合來擴大數位化參與，以減少疫苗接種缺口。製造商和服務提供者應投資於藥物警戒系統，以促進不利事件的透明報告並增強人們對疫苗安全性的信心。與動物收容所、動物福利組織、公共衛生機構和行動獸醫計畫建立合作關係可以改善服務不足人口獲得疫苗接種的機會。創新工作應著重於安全性、免疫持續時間、組合用藥的便利性、給藥的便利性以及經臨床檢驗的平台技術。領導者還應負責任地利用人工智慧來提高監測、合規性和營運效率，同時確保資料隱私、獸醫監管和法規遵循。

了解伴侶動物疫苗的調查方法

本執行摘要基於二級研究框架，重點關注經檢驗且有數據支持的來源，包括獸醫協會疫苗接種指南、監管出版刊物、公共衛生參考資料、同行評審的獸醫文獻、動物健康政策文件以及權威的疾病監測資訊來源。分析優先考慮與疫苗引入促進因素、感染疾病預防、當地公共衛生重點、獸醫基礎設施、監管實踐、寵物飼養趨勢以及技術驅動的醫療保健服務相關的定性資訊來源。透過比較臨床指南、政府資訊來源、學術出版物和產業相關獸醫文件中的資訊進行交叉檢驗。為符合既定研究範圍，本調查方法不涉及市場規模計算、市場估計、市場佔有率分析及預測。區域、群體和國家層面的洞察分析基於以下因素：獲得獸醫服務的便利性、狂犬病控制的重要性、伴侶動物飼養行為、監管成熟度、數位醫療的普及程度以及預防醫學意識。人工智慧 (AI) 的影響正在根據臨床決策支援、監測分析、藥物安全監測、物流和獸醫實踐管理等方面的已記錄用例進行評估，但人們也認知到臨床檢驗和監管仍然是必要的。

結論：透過伴侶動物疫苗促進預防醫學。

伴侶動物疫苗一直是預防獸醫學和公共衛生保護的基石。該領域正朝著更個人化、基於風險和數位化支持的免疫策略發展，從而提高接種依從性並加強疾病預防。區域差異顯著。成熟市場專注於方案最佳化、安全監測和飼主參與，而新興市場則更關注疫苗可近性、狂犬病預防、獸醫基礎設施和公眾意識。人工智慧 (AI) 預計將透過合規性追蹤、疾病監測、藥物安全監測和提高營運效率來增強整個生態系統，但其使用必須透明、安全且由獸醫主導。成功需要科學嚴謹性、負責任的創新、便利的分銷管道以及與寵物飼主的清晰溝通。那些能夠根據當地疾病風險、監管要求和不斷發展的寵物護理實踐調整疫苗接種策略的機構，將更有利於改善伴侶動物健康，並更好地實現「同一健康」目標。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 伴侶動物疫苗市場：依疫苗類型分類

  • 失活
    • 分裂細胞
    • 全細胞疫苗
  • 減毒活病毒疫苗
  • mRNA
  • 重組
  • 次單元
  • 類毒素

第8章 伴侶動物疫苗市場：依動物類型分類

  • 貓
  • 狗

第9章 伴侶動物疫苗市場：依給藥途徑分類

  • 黏膜
    • 鼻內
    • 口服
  • 腸外
    • 肌肉內部
    • 皮下

第10章：伴侶動物疫苗市場：依最終用戶分類

  • 動物診所
  • 動物醫院
  • 寵物飼主
  • 動物收容所
  • 研究機構

第11章 伴侶動物疫苗市場：依通路分類

  • 線上
    • 電子藥房
    • 製造商網站
  • 藥局
  • 動物診所
  • 動物醫院

第12章 伴侶動物疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 伴侶動物疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 伴侶動物疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Bimeda Biologicals Inc
  • Biogenesis Bago Animal Health SA
  • Biogenesis Bago SA
  • Biovet SA
  • Bioveta, as
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • Hipra SA
  • Indian Immunologicals Ltd.
  • Indian Immunologicals Ltd.
  • Jinyu Bio-technology Co., Ltd.
  • Kemin Industries, Inc.
  • Kyoritsu Seiyaku Corporation
  • Merck & Co., Inc.
  • Nisseiken Co., Ltd.
  • Phibro Animal Health Corporation
  • Qingdao Yebio Biological Engineering Co., Ltd.
  • Vaxxinova
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-957C47F94D1F

The Companion Animal Vaccine Market is projected to grow by USD 9.54 billion at a CAGR of 8.48% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.39 billion
Estimated Year [2026] USD 5.85 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 8.48%

Companion Animal Vaccine Market: Executive Introduction

The companion animal vaccine landscape is being shaped by rising pet ownership, heightened awareness of preventive veterinary care, expanding pet insurance adoption, and greater attention to zoonotic disease prevention. Vaccines for dogs, cats, and other companion animals remain central to routine wellness protocols, supporting protection against rabies, canine distemper, parvovirus, adenovirus, leptospirosis, feline panleukopenia, feline calicivirus, feline herpesvirus, and other infectious threats. Regulatory guidance and veterinary association recommendations continue to distinguish core vaccines, which are broadly recommended based on disease severity and public health relevance, from non-core vaccines, which are selected according to lifestyle, geography, exposure risk, and individual animal health status. Demand is further reinforced by urbanization, increased human-animal bonding, growth in veterinary clinic networks, and improved cold-chain and distribution capabilities. At the same time, the sector faces persistent challenges, including vaccine hesitancy among some pet owners, variable access to veterinary services, compliance gaps in booster schedules, and the need for transparent adverse event monitoring. The industry is therefore moving toward evidence-led immunization strategies that combine clinical efficacy, safety surveillance, owner education, and individualized veterinary decision-making.

Transformative Shifts in the Companion Animal Vaccine Landscape

The companion animal vaccine sector is undergoing structural change as veterinary medicine shifts from reactive treatment toward proactive, preventive care. Clinics are increasingly integrating vaccination with wellness examinations, parasite control, dental care, nutrition counseling, and digital health records, creating more consistent preventive health engagement. Another major transformation is the refinement of vaccination protocols around risk-based medicine. Rather than relying solely on standardized schedules, veterinarians increasingly evaluate lifestyle, travel patterns, boarding exposure, local disease prevalence, age, reproductive status, immune competence, and prior vaccine history. Advances in vaccine technology are also reshaping the landscape, including recombinant platforms, vector-based approaches, improved adjuvant systems, and combination vaccines designed to reduce handling stress and improve compliance. Public health priorities remain a major driver, particularly for rabies vaccination, where companion animal immunization is recognized as a key component of human rabies prevention under One Health strategies. Distribution models are also evolving, with veterinary hospitals, mobile clinics, shelters, animal welfare programs, and digitally enabled appointment ecosystems improving access. These shifts are creating a more data-informed, geographically responsive, and pet-owner-centric vaccine environment.

Cumulative Impact of Artificial Intelligence on Companion Animal Vaccines

Artificial intelligence is beginning to influence companion animal vaccination through clinical decision support, epidemiological monitoring, pharmacovigilance, customer engagement, and operational efficiency. AI-enabled veterinary practice systems can support reminders for booster compliance, identify pets at risk of missed vaccinations, and help clinics segment animals by age, breed, lifestyle, and local disease exposure. In disease surveillance, machine learning can analyze diagnostic records, geospatial signals, shelter intake patterns, laboratory submissions, and public health data to identify emerging infection clusters that may require targeted vaccine awareness. AI can also strengthen adverse event reporting by detecting patterns across large datasets, improving signal identification while supporting regulatory and clinical review. In product development, computational biology and predictive modeling can accelerate antigen selection, immune-response analysis, and formulation screening, although veterinary validation and regulatory evidence remain essential. For manufacturers, distributors, and veterinary service providers, AI can improve cold-chain monitoring, inventory planning, demand synchronization, and appointment scheduling. The cumulative impact is a transition from periodic vaccination transactions toward continuous preventive health management, provided that data privacy, interoperability, clinical oversight, and transparent model governance are maintained.

Key Regional Insights Across Companion Animal Vaccine Adoption

Asia-Pacific is characterized by rapid companion animal adoption, expanding urban middle-class pet spending, and growing demand for modern veterinary services across China, India, Japan, South Korea, Australia, and Southeast Asia. Rabies prevention remains a major public health priority in several countries, while higher-income markets emphasize premium veterinary care, lifestyle-based vaccination, and advanced clinic infrastructure. North America benefits from mature veterinary networks, high awareness of core vaccination protocols, broad availability of diagnostic and preventive care, and strong uptake of digital reminder systems that support compliance. The United States and Canada also maintain established rabies control frameworks, reinforcing the role of companion animal vaccination in public health. Latin America shows strong relevance for rabies vaccination, canine infectious disease prevention, and access expansion through public campaigns, private clinics, and animal welfare initiatives, with Brazil and Mexico serving as important veterinary care hubs. Europe is shaped by regulated veterinary standards, high pet humanization, cross-border pet travel requirements, and emphasis on pharmacovigilance, with companion animal vaccination closely linked to animal welfare and disease prevention policy. The Middle East is seeing increased pet ownership, premium clinic development, and greater focus on preventive veterinary services in urban centers, particularly across Gulf countries where imported pets and expatriate ownership patterns increase the importance of documentation and routine immunization. Africa presents a dual landscape, with growing urban pet care in major cities and continued reliance on rabies vaccination campaigns and One Health programs to reduce zoonotic disease risk, especially where access to routine veterinary services remains uneven.

Key Group Insights Shaping Companion Animal Vaccine Demand

Within ASEAN, companion animal vaccine adoption is influenced by rising pet ownership in urban centers, improving veterinary access, and continuing rabies prevention priorities in several member countries, making education, affordability, and cold-chain reach critical to broader immunization coverage. The GCC reflects a premiumization trend in companion animal care, supported by growing expatriate pet populations, modern veterinary clinics, and increasing demand for preventive health packages, although climate-sensitive logistics and import-dependent supply chains remain important considerations. The European Union provides a highly structured regulatory and animal health environment, where pet travel rules, veterinary pharmacovigilance, welfare policies, and harmonized standards support consistent vaccine quality and compliance. BRICS countries represent diverse but influential demand environments: China and India are expanding veterinary infrastructure and pet health awareness; Brazil has strong relevance in rabies and canine disease prevention; Russia maintains significant companion animal care needs across large geographies; and South Africa supports both private veterinary services and public health-linked vaccination priorities. G7 economies generally demonstrate mature veterinary care systems, high owner awareness, stronger data infrastructure, and established regulatory oversight, encouraging innovation in vaccine quality, safety monitoring, and compliance tools. NATO countries overlap substantially with developed veterinary markets in North America and Europe, where biosecurity awareness, cross-border mobility, and robust healthcare infrastructure reinforce preventive animal health practices, including companion animal vaccination.

Key Country Insights in Companion Animal Vaccine Adoption

The United States remains one of the most advanced companion animal vaccine environments, supported by extensive veterinary service availability, strong core vaccination awareness, state-level rabies requirements, and widespread use of wellness plans and digital reminders. Canada shows similar emphasis on preventive veterinary care, with rabies control requirements varying by province and local risk. Mexico combines private pet healthcare growth with ongoing public health relevance for rabies prevention. Brazil has a large companion animal population and long-standing public vaccination activity, particularly around rabies, while private clinics increasingly support broader canine and feline immunization. The United Kingdom emphasizes evidence-based vaccination protocols, pet travel compliance, and high owner engagement with veterinary preventive care. Germany, France, Italy, and Spain demonstrate strong veterinary infrastructure, high pet ownership, and regulatory alignment with European animal health standards, supporting consistent use of core and risk-based vaccines. Russia presents opportunities linked to companion animal care across major urban areas, though geographic scale can affect distribution consistency. China is experiencing rapid growth in pet healthcare awareness, urban clinic expansion, and demand for premium preventive services. India combines fast-rising pet ownership with major rabies prevention needs, making both public education and veterinary access essential. Japan has an established companion animal healthcare culture, aging pet demographics, and strong preventive care orientation. Australia benefits from high veterinary standards, biosecurity awareness, and strong owner willingness to invest in pet health. South Korea continues to see rapid pet humanization, urban veterinary clinic growth, and increasing interest in structured wellness and vaccination programs.

Actionable Recommendations for Companion Animal Vaccine Leaders

Industry leaders should prioritize evidence-based vaccine education for pet owners, emphasizing the distinction between core and non-core vaccines, the importance of booster compliance, and the role of vaccination in preventing zoonotic disease. Veterinary stakeholders should adopt risk-based protocols that account for geography, lifestyle, age, immune status, travel, boarding exposure, and local disease surveillance, while maintaining alignment with recognized veterinary guidelines and local regulations. Strengthening cold-chain reliability, inventory visibility, and last-mile distribution is essential, particularly in emerging markets and regions with temperature-sensitive logistics. Digital engagement should be expanded through automated reminders, electronic vaccination records, client education portals, and integration with wellness plans to reduce missed vaccinations. Manufacturers and service providers should invest in pharmacovigilance systems that encourage transparent adverse event reporting and support trust in vaccine safety. Partnerships with shelters, animal welfare groups, public health agencies, and mobile veterinary programs can improve access for underserved populations. Innovation efforts should focus on safety, duration of immunity, combination convenience, ease of administration, and clinically validated platform technologies. Leaders should also use AI responsibly to improve surveillance, compliance, and operational efficiency while ensuring data privacy, veterinary oversight, and regulatory alignment.

Research Methodology for Companion Animal Vaccine Insights

This executive summary is built using a secondary research framework focused on verified and data-backed sources, including veterinary association vaccination guidelines, regulatory agency publications, public health references, peer-reviewed veterinary literature, animal health policy documents, and recognized disease surveillance resources. The analysis prioritizes qualitative evidence related to vaccine adoption drivers, infectious disease prevention, regional public health priorities, veterinary infrastructure, regulatory practices, pet ownership trends, and technology-enabled care delivery. Cross-validation is applied by comparing information across clinical guidance, government sources, academic publications, and industry-relevant veterinary health documentation. The methodology excludes market sizing, market estimation, market share analysis, and forecasting to maintain compliance with the stated scope. Regional, group, and country insights are interpreted through factors such as veterinary access, rabies control relevance, companion animal ownership behavior, regulatory maturity, digital health adoption, and preventive care awareness. Artificial intelligence implications are assessed based on documented use cases in clinical decision support, surveillance analytics, pharmacovigilance, logistics, and veterinary practice management, while recognizing the continued need for clinical validation and regulatory oversight.

Conclusion: Advancing Preventive Health Through Companion Animal Vaccines

Companion animal vaccines remain a cornerstone of preventive veterinary medicine and public health protection. The sector is evolving toward more individualized, risk-based, and digitally supported immunization strategies that improve compliance and strengthen disease prevention. Regional dynamics differ significantly: mature markets emphasize protocol optimization, safety monitoring, and owner engagement, while emerging markets focus on access, rabies prevention, veterinary infrastructure, and awareness-building. Artificial intelligence is set to enhance the ecosystem through better compliance tracking, disease surveillance, pharmacovigilance, and operational efficiency, but its use must remain transparent, secure, and veterinarian-led. Success will depend on combining scientific rigor, responsible innovation, accessible distribution, and clear communication with pet owners. Organizations that align vaccination strategies with local disease risk, regulatory expectations, and evolving pet care behaviors will be best positioned to support healthier companion animals and stronger One Health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Companion Animal Vaccine Market, by Vaccine Type

  • 7.1. Introduction
  • 7.2. Inactivated
    • 7.2.1. Split Cell
    • 7.2.2. Whole Cell
  • 7.3. Live Attenuated
  • 7.4. mRNA
  • 7.5. Recombinant
  • 7.6. Subunit
  • 7.7. Toxoid

8. Companion Animal Vaccine Market, by Animal Type

  • 8.1. Introduction
  • 8.2. Cats
  • 8.3. Dogs

9. Companion Animal Vaccine Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Mucosal
    • 9.2.1. Nasal
    • 9.2.2. Oral
  • 9.3. Parenteral
    • 9.3.1. Intramuscular
    • 9.3.2. Subcutaneous

10. Companion Animal Vaccine Market, by End User

  • 10.1. Introduction
  • 10.2. Veterinary Clinics
  • 10.3. Veterinary Hospitals
  • 10.4. Pet Owners
  • 10.5. Animal Shelters
  • 10.6. Research Institutions

11. Companion Animal Vaccine Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Online
    • 11.2.1. E Pharmacies
    • 11.2.2. Manufacturer Websites
  • 11.3. Pharmacies
  • 11.4. Veterinary Clinics
  • 11.5. Veterinary Hospitals

12. Companion Animal Vaccine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Companion Animal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Bimeda Biologicals Inc
  • 16.2. Biogenesis Bago Animal Health S.A.
  • 16.3. Biogenesis Bago S.A.
  • 16.4. Biovet S.A.
  • 16.5. Bioveta, a.s.
  • 16.6. Boehringer Ingelheim International GmbH
  • 16.7. Ceva Sante Animale
  • 16.8. Dechra Pharmaceuticals PLC
  • 16.9. Elanco Animal Health Incorporated
  • 16.10. Hester Biosciences Limited
  • 16.11. Hipra S.A.
  • 16.12. Indian Immunologicals Ltd.
  • 16.13. Indian Immunologicals Ltd.
  • 16.14. Jinyu Bio-technology Co., Ltd.
  • 16.15. Kemin Industries, Inc.
  • 16.16. Kyoritsu Seiyaku Corporation
  • 16.17. Merck & Co., Inc.
  • 16.18. Nisseiken Co., Ltd.
  • 16.19. Phibro Animal Health Corporation
  • 16.20. Qingdao Yebio Biological Engineering Co., Ltd.
  • 16.21. Vaxxinova
  • 16.22. Vetoquinol S.A.
  • 16.23. Virbac S.A.
  • 16.24. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COMPANION ANIMAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL COMPANION ANIMAL VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SPLIT CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SPLIT CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SPLIT CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WHOLE CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WHOLE CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL WHOLE CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CATS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MUCOSAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MUCOSAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MUCOSAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PET OWNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PET OWNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PET OWNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL SHELTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL SHELTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL SHELTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL E PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL E PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL E PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 204. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 207. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 208. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 348. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA COMPANION ANIMAL VACCINE MARKET S